Moderna, Inc. (MRNA) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Edward Tenthoff
Piper Sandler & Co., Research Division

Next presenting company, Moderna. My name is Ted Tenthoff. I’m a senior biotech analyst at Piper Sandler. And before I begin, I am required to point out certain disclosures regarding the relationship between Piper and Moderna that are listed at the back of the room and also at the registration desk.

So as you know, Moderna is a leading developer of messenger RNA vaccines and medicines. Moderna shares have been under pressure over the last couple of years after really helping us through the COVID pandemic, in part as a result of decreasing immunization rates. I got my mNEXSPIKE vaccine. I think anyone who gets a flu shot should get a COVID vaccine as well as long as they’re recommended by their doctor. And now under the FDA and RFK Jr., it really feels like they’ve declared war on mRNA vaccines. And then we recently had the setback with the same victory. So it’s been a tough slog here. But you guys just recently had an R&D Day and really pointed to all of the new vaccines and medicines that are coming. And I think it’s a really exciting time. And Jamie, you always do such a great job going through sort of the financial underpinnings of what Stephane and Stephen and everyone are working on and how you’re going to get there.

So I’m pleased to introduce Jamie Mock, CFO.